NCT04651920View on ClinicalTrials.gov

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

November 26, 2020

Primary Completion Date

March 26, 2022

Study Completion Date

March 26, 2022

Conditions
Epithelial Ovarian CancerChineseHomologous Recombination DeficiencyBRCA1 MutationBRCA2 MutationPrognosisHomologous Recombination Genes
Interventions
GENETIC

Evaluation of homologous recombination deficiency score

Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)

Trial Locations (1)

100730

Lei Li, Beijing

All Listed Sponsors
lead

Lei Li

OTHER

NCT04651920 - A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter